Journey Medical Shares Drop—DERM’s 2026 Outlook Hinges on Emrosi Trial
Journey Medical Corp was down 3.5% at $6.09 late Monday, putting the company's market cap around $166 million. The Scottsdale-based maker of dermatology drugs trailed the SPDR S&P Biotech ETF, which slipped 2.2%. No new company statement has landed in the past two days. Journey’s investor page still shows the last update as May 19, when it flagged its slot at A.G.P.’s Annual Virtual Healthcare Conference. Before that, the site posted Journey’s May 13 Q1 earnings.